Refractive and Biometric Outcomes Following Intravitreal Injection of Ranibizumab in Retinopathy of Prematurity: A Long -Term Study.

Résumé

Abstract Objective: To evaluate the long-term effects of intravitreal injection of ranibizumab (IVR) as monotherapy for ROP on refractive and biometric ocular parameters. Methods: This prospective case-control study included three groups were included: the injection group (premature infants who received single IVR) and two control groups: spontaneous ROP regression and premature children with no ROP. Spherical equivalent (SE), average keratometry (AVG-K), anterior chamber depth (ACD), lens thickness (LT), and axial length (AL) were analyzed at ages of > 1 year and >5 years. Results: Compared to the control groups, the injection group had a higher prevalence of very high myopia and high myopia at both visits, a significantly longer AL (P = 0.017) and higher LT (P <0.001) at the age of > 1 year and a significantly higher AVG-K (P= 0.003) and AL (P = 0.044) at the age of >5 years. The injection group showed a significant increase (P <0.001) in SE, AVG-K, ACD, and AL (P = 0.008) with decrease in LT (P= 0.003) at the second visit compared to the first one. Conclusion: ROP treatment with IVR is associated with a high prevalence of high myopia and very high myopia, which is related to a longer AL, anterior segment changes, and disease severity. Continuous monitoring of the refractive status following IVR treatment is recommended to avoid the risk of amblyopia.

Citer ce document

Accès au document

Texte intégral en lecture en ligne, réservé aux abonnés SPHAERO et aux membres de l'institution. Se connecter

Auteur(s)

Statistiques

Consultations : 1

Téléchargements : 0